access to specialized multidisciplinary oncology teams may
not be available.
LIMITATIONS
A small panel of physicians developed the algorithm,
representing a few centers, and did not include patients
in the development. While alternatives for prevention
and management of cAEs could exist, the statements are
suggestions for best practice developed from a panel of expert
clinicians supported by peer-reviewed literature. Although
limited evidence was available to guide the development
of the algorithm, the project will hopefully encourage more
skincare studies to prevent and treat cAEs.
CONCLUSIONS
A multidisciplinary team treating and guiding the cancer
patient may improve cancer treatment tolerance. The USCOM
algorithm on general skincare measures, including cleansers
and moisturizers to prevent or reduce the severity of cAEs,
may increase awareness and help improve cancer patient
outcomes.
DISCLOSURE AND ACKNOWLEDGMENTS
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by unrestricted educational grant from La Roche-Posay US. Dr. Lacouture has a consultant role with Johnson and Johnson, Novocure, QED, Bicara, Janssen, Novartis, F. Hoffmann-La Roche AG, EMD Serono, Astrazeneca, Innovaderm, Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genentech, Loxo, Seattle Genetics, Lutris, OnQuality, Azitra, Roche, Oncoderm, NCODA, Apricity. Dr. Lacouture also receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis and AZ and is funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.
All authors contributed to the development of this work and its review and agreed with its content.
All authors contributed to the development of this work and its review and agreed with its content.
REFERENCES
1. Siegel RL, Miller KD, Ahmedin J. Cancer statistics 2019. CA Cancer J Clin 2019;69:7-34. doi: 10.3322/caac.21551. Available online at cacancerjournal.com.
2. Ferlay J, Colombet M, Soerjomataram I, et al. Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018. International Agency for Research on Cancer/World Health Organization; 2018.
3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2017, National Cancer Institute. Published April 2020. https://seer. cancer.gov/csr/1975_2017/
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
5. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients/ [edited by] Mario E Lacouture: Wiley Blackwell, Hoboken New Jersey, USA 2014. ISBN 978-0-470-62188-2.
6. Lee J, Lim J, Park JS, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat. 2018 Oct;50(4):1186-93.
7. Lacouture M E. et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(8):1351-7.
8. Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19(5):477-482.
9. Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related cAEs. J Am Acad Dermatol. 2020;82(4):994-996.
10. Barrios DM, Phillips GS, Feites-Martinez A, Hsu M, Ciccolini K, Skripnik Lucas A, Marchetti MA, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol 2020;34(6):1340-1347. doi: 10.1111/jdv.16159.
11. Barrios DCK, Phillips G, Lucas AS, et al. Anticancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at MSKCC. J Am Acad Dermatol. 2017;76(6): AB45.
12. Sauder MB, Addona M, Andriessen A, et al. The role of skin care in oncology patients. Skin Ther Letter; 2020 Oct(10):1-12. https://www.skintherapyletter. com/wp-content/uploads/2020/10/STL-digital-oncology-skincare.pdf
13. Brouwers M, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in healthcare. Can Med Assn J. 2010;182:E839-42.
14. Trevelyan EG, Robinson N. (2015). Delphi methodology in health research: how to do it? Eur J Integ Med. 2015;7(4):423-428.
15. Smith Begolka W, Elston DM, Beutner KR. American Academy of Dermatology evidence-based guideline development process: responding to new challenges and establishing transparency. J Am Acad Dermatol. 2011;64(6):e105-12. doi: 10.1016/j.jaad.2010.10.029.
16. Guenther L. Presentation at Derm. Update, Fall 2018, Montreal, Canada. http://www.slideshare.net/jrcampos/03-algorithm-properties 17. Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR. Evaluation of a comprehensive skin toxicity program for patients treated with EGFRi. JAMA Dermatol. 2020;e201795.
18. Dreno B, Bensadoun RJ, Humbert P, Krutmann J et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venerol. 2013;27:1071–1080.
19. Schnur JB, Quellette SC, Dilorenzo TA, et al. A quantitative analysis of acute skin toxicity among breast cancer radiotherapy patients. Psychooncology. 2011;20(3):260-8.
20. Leventhal J, Young MR. Radiation dermatitis: recognition, prevention, and management. Oncology (Williston Park). 2017;31(12):885-894.
21. Dermatitis Radiation Grading (CTCAE v5) https://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm#ctc_50
22. Rosenthal A, Irailevich R, Mov R. Management of acute radiation dermatitis: a review of the literature and proposal for treatment algorithm. J Am Acad Dermatol. 2019;81(2):558-67.
23. Biswal SG, Mehta RD. Cutaneous adverse reactions of chemotherapy in cancer patients: A clinicoepidemiological study. Indian J Dermatol. 2018;63(1):41-6.
24. Ferreira MN, Ramseier JY, Leventhal S. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5(5):285- 307.
25. Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010;14(4):337-49.
26. Grande R, Narducci F, Bianchetti S, et al. Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and lymecycline. A phase II study. Support Care Cancer. 2013;21(6):1691-5.
27. Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221-36.
28. Ng CY, Chen CB, Wu MY, et al Anticancer drugs induced severe adverse
2. Ferlay J, Colombet M, Soerjomataram I, et al. Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018. International Agency for Research on Cancer/World Health Organization; 2018.
3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2017, National Cancer Institute. Published April 2020. https://seer. cancer.gov/csr/1975_2017/
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
5. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients/ [edited by] Mario E Lacouture: Wiley Blackwell, Hoboken New Jersey, USA 2014. ISBN 978-0-470-62188-2.
6. Lee J, Lim J, Park JS, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat. 2018 Oct;50(4):1186-93.
7. Lacouture M E. et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(8):1351-7.
8. Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19(5):477-482.
9. Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related cAEs. J Am Acad Dermatol. 2020;82(4):994-996.
10. Barrios DM, Phillips GS, Feites-Martinez A, Hsu M, Ciccolini K, Skripnik Lucas A, Marchetti MA, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol 2020;34(6):1340-1347. doi: 10.1111/jdv.16159.
11. Barrios DCK, Phillips G, Lucas AS, et al. Anticancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at MSKCC. J Am Acad Dermatol. 2017;76(6): AB45.
12. Sauder MB, Addona M, Andriessen A, et al. The role of skin care in oncology patients. Skin Ther Letter; 2020 Oct(10):1-12. https://www.skintherapyletter. com/wp-content/uploads/2020/10/STL-digital-oncology-skincare.pdf
13. Brouwers M, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in healthcare. Can Med Assn J. 2010;182:E839-42.
14. Trevelyan EG, Robinson N. (2015). Delphi methodology in health research: how to do it? Eur J Integ Med. 2015;7(4):423-428.
15. Smith Begolka W, Elston DM, Beutner KR. American Academy of Dermatology evidence-based guideline development process: responding to new challenges and establishing transparency. J Am Acad Dermatol. 2011;64(6):e105-12. doi: 10.1016/j.jaad.2010.10.029.
16. Guenther L. Presentation at Derm. Update, Fall 2018, Montreal, Canada. http://www.slideshare.net/jrcampos/03-algorithm-properties 17. Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR. Evaluation of a comprehensive skin toxicity program for patients treated with EGFRi. JAMA Dermatol. 2020;e201795.
18. Dreno B, Bensadoun RJ, Humbert P, Krutmann J et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venerol. 2013;27:1071–1080.
19. Schnur JB, Quellette SC, Dilorenzo TA, et al. A quantitative analysis of acute skin toxicity among breast cancer radiotherapy patients. Psychooncology. 2011;20(3):260-8.
20. Leventhal J, Young MR. Radiation dermatitis: recognition, prevention, and management. Oncology (Williston Park). 2017;31(12):885-894.
21. Dermatitis Radiation Grading (CTCAE v5) https://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm#ctc_50
22. Rosenthal A, Irailevich R, Mov R. Management of acute radiation dermatitis: a review of the literature and proposal for treatment algorithm. J Am Acad Dermatol. 2019;81(2):558-67.
23. Biswal SG, Mehta RD. Cutaneous adverse reactions of chemotherapy in cancer patients: A clinicoepidemiological study. Indian J Dermatol. 2018;63(1):41-6.
24. Ferreira MN, Ramseier JY, Leventhal S. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol. 2019;5(5):285- 307.
25. Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010;14(4):337-49.
26. Grande R, Narducci F, Bianchetti S, et al. Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and lymecycline. A phase II study. Support Care Cancer. 2013;21(6):1691-5.
27. Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221-36.
28. Ng CY, Chen CB, Wu MY, et al Anticancer drugs induced severe adverse
